Unity Biotechnology, Inc.
Unity Biotechnology, Inc. (UBX): 1 pipeline candidate · ~8 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
8.2 months
D/E -149.03 · 0% dilution
Lead: Phase 2
1 candidate
N/A
N/A
A transparent, data-derived signal for Unity Biotechnology, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$8.9M
Quarterly Burn
$6.4M
Runway
8.2 mo
Revenue
$0
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| foselutoclax | Phase 2 |
Frequently asked questions
How many drug candidates are in Unity Biotechnology, Inc.'s pipeline?
Unity Biotechnology, Inc. (UBX) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is Unity Biotechnology, Inc.'s lead drug candidate?
Unity Biotechnology, Inc.'s most advanced tracked candidate is foselutoclax (Phase 2) for Diabetic Macular Edema.
What is Unity Biotechnology, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Unity Biotechnology, Inc. has approximately 8.2 months of cash runway.
Who is the CEO of Unity Biotechnology, Inc.?
Anirvan Ghosh is the chief executive officer of Unity Biotechnology, Inc. (UBX).
Get the full picture on Unity Biotechnology, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.